The contradiction implies the existence of immunosuppression in the TGF‐β dominant subtype, consistent with our finding that two cancer stem cell–specific immune checkpoints were higher in the TGF‐β dominant subtype than in other immune subtypes. This evidence concerns the gene TGFB1 and cancer.